MKMichael John Kerins

Michael John Kerins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael John Kerins has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Aikseng Ooi

    Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA

    6 shared publications
  • Donna D. Zhang

    Department of Molecular Medicine, Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, United States of America

    3 shared publications
  • Pengfei Liu

    §University of Arizona Cancer Center, University of Arizona, Tucson, Arizona 85721

    3 shared publications
  • Aikseng Ooi

    Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721

    2 shared publications
  • Brandon John Praslicka

    Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona

    2 shared publications
  • Emily J. Guinn

    2 shared publications

Latest Publications

  • Open Access

    Differential and overlapping targets of the transcriptional regulators NRF1, NRF2, and NRF3 in human cells

    by Pengfei Liu, Michael J. Kerins, Wang Tian, Durga Neupane, Donna D. Zhang, Aikseng Ooi


  • Genome-Wide CRISPR Screen Reveals Autophagy Disruption as the Convergence Mechanism That Regulates the NRF2 Transcription Factor

    by Michael J. Kerins, Pengfei Liu, Wang Tian, William Mannheim, Donna D. Zhang, Aikseng Ooi

    The nuclear factor (erythroid 2)-like 2 (NRF2 or NFE2L2) transcription factor regulates the expression of many genes that are critical in maintaining cellular homeostasis. Its deregulation has been implicated in many diseases, including cancer and metabolic and neurodegenerative diseases. While several mechanisms by which NRF2 can be activated have gradually been identified over time, a more complete regulatory network of NRF2 is still lacking. Here we show through a genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screen that a total of 273 genes, when knocked out, will lead to sustained NRF2 activation. Pathway analysis revealed a significant overrepresentation of genes (18 of the 273 genes) involved in autophagy. Molecular validation of a subset of the enriched genes identified 8 high-confidence genes that negatively regulate NRF2 activity irrespective of cell type: ATG12, ATG7, GOSR1, IFT172, NRXN2, RAB6A, VPS37A, and the well-known negative regulator of NRF2, KEAP1. Of these, ATG12, ATG7, KEAP1, and VPS37A are known to be involved in autophagic processes. Our results present a comprehensive list of NRF2 negative regulators and reveal an intimate link between autophagy and NRF2 regulation.


  • Top Cited Papers
    Open Access

    The Roles of NRF2 in Modulating Cellular Iron Homeostasis

    by Michael John Kerins, Aikseng Ooi

    Significance: Iron and oxygen are intimately linked: iron is an essential nutrient utilized as a cofactor in enzymes for oxygen transport, oxidative phosphorylation, and metabolite oxidation. However, excess labile iron facilitates the formation of oxygen-derived free radicals capable of damaging biomolecules. Therefore, biological utilization of iron is a tightly regulated process. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor, which can respond to oxidative and electrophilic stress, regulates several genes involved in iron metabolism. Recent Advances: The bulk of NRF2 transcription factor research has focused on its roles in detoxification and cancer prevention. Recent works have identified that several genes involved in heme synthesis, hemoglobin catabolism, iron storage, and iron export are under the control of NRF2. Constitutive NRF2 activation and subsequent deregulation of iron metabolism have been implicated in cancer development: NRF2-mediated upregulation of the iron storage protein ferritin or heme oxygenase 1 can lead to enhanced proliferation and therapy resistance. Of note, NRF2 activation and alterations to iron signaling in cancers may hinder efforts to induce the iron-dependent cell death process known as ferroptosis. Critical Issues: Despite growing recognition of NRF2 as a modulator of iron signaling, exactly how iron metabolism is altered due to NRF2 activation in normal physiology and in pathologic conditions remains imprecise; moreover, the roles of NRF2-mediated iron signaling changes in disease progression are only beginning to be uncovered. Future Directions: Further studies are necessary to connect NRF2 activation with physiological and pathological changes to iron signaling and oxidative stress. Antioxid. Redox Signal. 00, 000–000.


  • RPA1 binding to NRF2 switches ARE-dependent transcriptional activation to ARE-NRE–dependent repression

    by Pengfei Liu, Montserrat Rojo de la Vega, Saad Sammani, Joseph B. Mascarenhas, Michael Kerins, Matthew Dodson, Xiaoguang Sun, Ting Wang, Aikseng Ooi, Joe G. N. Garcia, et al.

    Significance: Our findings shift the paradigm of NRF2 as a transcriptional activator to one in which NRF2 can also act as a transcriptional repressor, which we believe will stimulate new research areas and interests among scientists from other fields. While the majority of the data provided in this paper center on suppression of MYLK expression and the resulting pathological significance, the more far-reaching findings are the in silico and RNA-seq datasets indicating that the NRF2-replication protein A1 (RPA1)-ARE-NRE complex transcriptionally represses other genes as well, again highlighting the broad scope and significance of NRF2 repression of target genes.


  • Open Access

    A catalogue of somatic NRF2 gain-of-function mutations in cancer

    by Michael John Kerins, Aikseng Ooi

    Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), are frequently mutated in cancer. These mutations drive constitutive NRF2 activation and correlate with poor prognosis. Despite its apparent significance, a comprehensive catalogue of somatic NRF2 mutations across different tumor types is still lacking. Here, we catalogue NRF2 mutations in The Cancer Genome Atlas (TCGA) database. 226 unique NRF2-mutant tumors were identified from 10,364 cases. NRF2 mutations were found in 21 out of the 33 tumor types. A total of 11 hotspots were identified. Of these, mutation to the R34 position was most frequent. Notably, R34 and D29 mutations were overrepresented in bladder, lung, and uterine cancers. Analyses of corresponding RNA sequencing data using a de novo derived gene expression classifier showed that the R34 mutations drive constitutive NRF2 activation with a selection pressure biased against the formation of R34L. Of all R34 mutants, R34L conferred the least degree of protein stabilization, suggesting a pro-tumor NRF2 half-life threshold. Our findings offer a comprehensive catalogue of NRF2 mutations in cancer that can help prognostication and NRF2 research.


  • Open Access

    Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction

    by Michael John Kerins, John Milligan, James Akira Wohlschlegel, Aikseng Ooi

    Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome characterized by inactivation of the Krebs cycle enzyme fumarate hydratase (FH). HLRCC patients are at high risk of developing kidney cancer of type 2 papillary morphology that is refractory to current radiotherapy, immunotherapy and chemotherapy. Hence, an effective therapy for this deadly form of cancer is urgently needed. Here, we show that FH inactivation (FH−/−) proves synthetic lethal with inducers of ferroptosis, an iron‐dependent and nonapoptotic form of cell death. Specifically, we identified gene signatures for compound sensitivities based on drug responses for 9 different drug classes against the NCI‐60 cell lines. These signatures predicted that ferroptosis inducers would be selectively toxic to FH−/− cell line UOK262. Preferential cell death against UOK262‐FH−/− was confirmed with 4 different ferroptosis inducers. Mechanistically, the FH−/− sensitivity to ferroptosis is attributed to dysfunctional GPX4, the primary cellular defender against ferroptosis. We identified that C93 of GPX4 is readily post‐translationally modified by fumarates that accumulate in conditions of FH−/−, and that C93 modification represses GPX4 activity. Induction of ferroptosis in FH‐inactivated tumors represents an opportunity for synthetic lethality in cancer.


  • Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes

    by Michael John Kerins, Ajay Amar Vashisht, Benjamin Xi-Tong Liang, Spencer Jordan Duckworth, Brandon John Praslicka, James Akira Wohlschlegel, Aikseng Ooi

    Germ line mutations of the gene encoding the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) cause a hereditary cancer syndrome known as hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC-associated tumors harbor biallelic FH inactivation that results in the accumulation of the TCA cycle metabolite fumarate. Although it is known that fumarate accumulation can alter cellular signaling, if and how fumarate confers a growth advantage remain unclear. Here we show that fumarate accumulation confers a chronic proliferative signal by disrupting cellular iron signaling. Specifically, fumarate covalently modifies cysteine residues on iron regulatory protein 2 (IRP2), rendering it unable to repress ferritin mRNA translation. Simultaneously, fumarate increases ferritin gene transcription by activating the NRF2 (nuclear factor [erythroid-derived 2]-like 2) transcription factor. In turn, increased ferritin protein levels promote the expression of the promitotic transcription factor FOXM1 (Forkhead box protein M1). Consistently, clinical HLRCC tissues showed increased expression levels of both FOXM1 and its proliferation-associated target genes. This finding demonstrates how FH inactivation can endow cells with a growth advantage.


  • The complex role of NRF2 in cancer: A genomic view

    by Brandon John Praslicka, Michael John Kerins, Aikseng Ooi


  • Correction to “Quantifying Functional Group Interactions That Determine Urea Effects on Nucleic Acid Helix Formation”

    by Emily J. Guinn, Jeffrey J. Schwinefus, Hyo Keun Cha, Joseph L. McDevitt, Wolf E. Merker, Ryan Ritzer, Gregory W. Muth, Samuel W. Engelsgjerd, Kathryn E. Mangold, Perry J. Thompson, et al.


  • Quantifying Functional Group Interactions That Determine Urea Effects on Nucleic Acid Helix Formation

    by Emily J. Guinn, Jeffrey J. Schwinefus, Hyo Keun Cha, Joseph L. McDevitt, Wolf E. Merker, Ryan Ritzer, Gregory W. Muth, Samuel W. Engelsgjerd, Kathryn E. Mangold, Perry J. Thompson, et al.

    Urea destabilizes helical and folded conformations of nucleic acids and proteins, as well as protein–nucleic acid complexes. To understand these effects, extend previous characterizations of interactions of urea with protein functional groups, and thereby develop urea as a probe of conformational changes in protein and nucleic acid processes, we obtain chemical potential derivatives (μ23 = dμ2/dm3) quantifying interactions of urea (component 3) with nucleic acid bases, base analogues, nucleosides, and nucleotide monophosphates (component 2) using osmometry and hexanol–water distribution assays. Dissection of these μ23 values yields interaction potentials quantifying interactions of urea with unit surface areas of nucleic acid functional groups (heterocyclic aromatic ring, ring methyl, carbonyl and phosphate O, amino N, sugar (C and O); urea interacts favorably with all these groups, relative to interactions with water. Interactions of urea with heterocyclic aromatic rings and attached methyl groups (as on thymine) are particularly favorable, as previously observed for urea–homocyclic aromatic ring interactions. Urea m-values determined for double helix formation by DNA dodecamers near 25 °C are in the range of 0.72–0.85 kcal mol–1m–1 and exhibit little systematic dependence on nucleobase composition (17–42% GC). Interpretation of these results using the urea interaction potentials indicates that extensive (60–90%) stacking of nucleobases in the separated strands in the transition region is required to explain the m-value. Results for RNA and DNA dodecamers obtained at higher temperatures, and literature data, are consistent with this conclusion. This demonstrates the utility of urea as a quantitative probe of changes in surface area (ΔASA) in nucleic acid processes.